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ABSTRACT
ObjectiveaaPatients with drug-induced parkinsonism (DIP) may have nigrostriatal dopaminergic degeneration. We studied 
the clinical features that may indicate nigrostriatal dopaminergic degeneration in patients with DIP.
MethodsaaForty-one DIP patients were classified into normal and abnormal [18F] FP-CIT scan groups. Differences in 32 clini-
cal features and drug withdrawal effects were studied.
ResultsaaTwenty-eight patients had normal (Group I) and 13 patients had abnormal (Group II) scans. Eight patients of Group 
I, but none of Group II, had taken calcium channel blockers (p = 0.040). Three patients of Group I and six of Group II had hy-
posmia (p = 0.018). After drug withdrawal, Group I showed greater improvement in Unified Parkinson’s Disease Rating Scale 
total motor scores and subscores for bradykinesia and tremors than Group II. Only hyposmia was an independent factor associ-
ated with abnormal scans, but it had suboptimal sensitivity.
ConclusionaaNone of the clinical features were practical indicators of nigrostriatal dopaminergic degeneration in patients with 
DIP.
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JMD
Nigrostriatal dopaminergic degeneration is found in 30 to 
75% of patients clinically diagnosed with drug-induced parkin-
sonism (DIP).1-4 Dopamine transporter (DAT) single photon 
emission computed tomography (SPECT) and photon emission 
tomography (PET) studies of DIP showed that patients with 
normal scans have dopa-resistant parkinsonism that may not 
progress even if the offending drug treatment is continued. Con-
versely, patients with reduced striatal uptake have dopa-respon-
sive parkinsonism that may deteriorate even after drug withdraw-
al.3-6 Thus, clinical features must be defined to help differentiate 
DIP patients with normal and abnormal scans. DAT imaging 
evaluates the striatal presynaptic dopaminergic function and is 
useful for the differential diagnosis of parkinsonism and the as-
sessment of severity and progression.7,8 Additionally, [18F] N-(3-
fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane 
(FP-CIT) is superior to SPECT because of its better spatial reso-
lution.8
Three DAT SPECT studies from the same group reported that 
compared to DIP patients with normal scans, those with abnor-
mal scans were older, more frequently had asymmetric and se-
vere parkinsonism, and less frequently had bucco-linguo-masti-
catory (BLM) dyskinesia.2,4,9 One DAT PET study also showed 
that DIP patients with normal scans had more frequent sym-
metric parkinsonism compared to abnormal ones.10 Conversely, 
four other SPECT studies did not find differences in clinical fea-
tures between patients with normal and abnormal scans.1,5,11,12 
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However, those four studies included only 13 to 22 
patients with DIP.
In 41 patients with DIP, we studied demographic 
and clinical parameters that may differentiate DIP 
patients with normal and abnormal [18F] FP-CIT 
PET scans. In 31 of the 41 patients, we studied wheth-
er DIP patients with normal and abnormal scans 
could be differentiated by changes in Unified Parkin-
son’s Disease Rating Scale (UPDRS) scores after drug 
withdrawal.
MATERIALS & METHODS
Patients
We reviewed the medical records of 41 DIP pa-
tients who underwent brain MRI and DAT PET 
studies. DIP was diagnosed according to parameters 
described in a previous report: the presence of two 
or more cardinal symptoms of parkinsonism, no his-
tory of parkinsonism before use of the offending 
drug and onset of parkinsonism symptoms during 
use of the offending drug.13 Patients were excluded if 
they had signs compatible with atypical parkinson-
ism and other causes of secondary parkinsonism. In 
31 of the 41 patients, we evaluated changes in par-
kinsonian motor deficits after withdrawal of the of-
fending drug. The present study was approved by the 
Institutional Review Board of the Gangnam Sever-
ance Hospital, Yonsei University College of Medicine 
(IRB # 3-2016-0018).
Methods
We recorded the demographics, duration of par-
kinsonism, family history of parkinsonism, smoking 
history, and offending drug histories. We collected 
data about falls, aspiration, dysarthria, and BLM 
dyskinesia. We registered initial parkinsonian symp-
toms including asymmetry. We collected data on 
non-motor symptoms and Mini-Mental State Ex-
amination (MMSE) scores.
We measured UPDRS motor scores and counted 
patients who presented with asymmetric parkinso-
nian motor deficits (≥ 4 side to side difference in 
UPDRS motor score).9 We also computed indexes of 
asymmetric parkinsonian motor deficits (sum of 
UPDRS motor scores of the more affected side di-
vided by that of the less affected side) and dispropor-
tionate arm involvement (sum of UPDRS motor 
scores of the arms divided by that of the legs). In 31 
of 41 patients, changes in UPDRS total motor scores 
and subscores for bradykinesia, rigidity, tremors, and 
axial motor deficits were measured after withdrawal 
of the drug for at least 2 months.
Quantitative measurements of PET images were 
performed as reported previously by our study group.14 
We considered a scan as abnormal when the mean 
bilateral putamen DAT uptake was reduced more 
than two standard deviations from that of 36 age-
matched healthy controls who had no history of 
neurological illness and no abnormal signs on neu-
rological examination. We classified patients into 
normal and abnormal scan groups.
Statistics
Using chi-square tests (Fisher’s exact tests) for cat-
egorical variables and independent two sample t-
tests for continuous variables, we examined the group 
differences for all the parameters. For the parameters 
with significant group differences, we performed 
univariate and multivariate backward binary logistic 
regression analyses controlled for age and sex to 
identify independent factors in distinguishing DIP 
with normal and abnormal scans. For the use of cal-
cium channel blockers (CCBs), exact binary logistic 
regression analysis was performed using Statistical 
Analysis System software (SAS version 9.1; SAS Inc., 
Cary, NC, USA). All other statistical analyses were 
performed using SPSS (version 23.0; SPSS Inc., Chi-
cago, IL, USA). The results were considered statisti-
cally significant when the p-value was < 0.05.
RESULTS
Twenty-eight patients (Group I; 68.3%) had nor-
mal scans and 13 (Group II; 31.7%) had abnormal 
scans. The mean age at onset was similar between 
Group I and II. Women were more prevalent than 
men in both groups. There was no significant group 
difference in female predominance. The means of 
the duration of parkinsonism were not significantly 
different (Table 1).
In both groups, common causative drugs were an-
tiemetics and antidepressants. Eight patients of Group 
I, but none of Group II, had taken CCBs (p = 0.040). 
Multiple drug therapy was common in both groups 
(Supplementary Table 1 in the only online Data Sup-
plement). The duration of exposure to drugs for 
Group I was longer than Group II, but the difference 
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was not significant (Table 1).
The frequencies of various non-motor deficits 
were not significantly different between groups. How-
ever, compared to Group I, Group II patients had 
more frequent hyposmia (p = 0.018). There was no 
significant group difference in the mean MMSE 
scores or the frequency of dementia (MMSE score ≤ 
24) (Table 2).
Compared to Group I, Group II patients more of-
ten had a history of falls, aspiration, and dysarthria, 
but the differences were not significant. BLM dyski-
nesia was uncommon in both groups. In both groups, 
tremors and gait disturbances were common initial 
symptoms. There was no significant difference in the 
frequency of asymmetric onset (Table 2).
The means of UPDRS total motor scores of Group 
I and II were similar. In addition, there were no sig-
nificant differences in subscores for bradykinesia, ri-
gidity, tremor or axial motor impairments. Four pa-
tients (14.3%) of Group I and three patients (23.1%) 
of Group II had asymmetric parkinsonism. There 
were no significant differences in the UPDRS index-
es of asymmetry or disproportionate upper-to-lower 
involvement of the extremities (Supplementary Table 
2 in the only online Data Supplement).
In 31 patients (Group I = 20 patients; Group II = 
11 patients), changes in UPDRS scores were mea-
sured after a mean of 4.03 months of drug with-
drawal. Compared to Group II, Group I showed 
greater reductions in UPDRS total motor scores 
(-8.75 ± 9.16 vs. 0.18 ± 7.76; p = 0.011) and subscores 
for bradykinesia (p = 0.029), total tremors (p = 0.019), 
and resting tremors (p = 0.021). However, there were 
no differences in residual parkinsonian motor defi-
cits and changes in the indexes of asymmetry or dis-
proportionate upper-to-lower involvement of the ex-
tremities (Supplementary Table 2 in the only online 
Data Supplement).
Univariate regression analyses showed that the fre-
quency of hyposmia (p = 0.017) and greater reduc-
tions in total motor scores (p = 0.040) and subscores 
for bradykinesia (p = 0.047) after drug withdrawal 
were associated with abnormal scans (Supplementary 
Table 3 in the only online Data Supplement). Using 
multivariate regression analysis, only the frequency of 
hyposmia was an independent factor associated with 
abnormal scans (p = 0.030) (Supplementary Table 3 
in the only online Data Supplement). Hyposmia had 
relatively high specificity (89.3%) and negative pre-
dictive value (78.1%) but had low sensitivity (46.2%) 
and positive predictive value (66.7%) for abnormal 
scans.
DISCUSSION
In the present study, we performed a systematic 
analysis of 32 clinical parameters between patients 
with normal and abnormal DAT scans. Compared 
to DIP patients with normal scans, those with ab-
normal scans had more frequent hyposmia. No pa-
Table 1. Demographics and clinical characteristics of 41 patients with drug-induced 
parkinsonism with normal and reduced putamen FP-CIT uptake
Group I (n = 28) Group II (n = 13) p value
Age at onset (yrs) 71.29 ± 9.34 67.38 ± 8.88 0.214
Age at examination (yrs) 72.72 ± 9.68 68.46 ± 8.84 0.187
Gender (male: female) 5:23 (82.1) 5:8 (61.5) 0.241
Duration of drug exposure (mo)* 4.66 ± 3.79 3.04 ± 2.96 0.182
Duration of parkinsonism (mo)† 14.16 ± 14.54 15.54 ± 15.44 0.783
Family history of parkinsonism 2 (7.1) 1 (7.7) > 0.999
Smoking history 1 (3.6) 2 (15.4) 0.232
Group I: normal putamen FP-CIT uptake, Group II: reduced putamen FP-CIT uptake. Mean 
± standard deviation, numbers in parentheses = %. *duration of drug exposure prior to 
symptom onset (mo), †duration of parkinsonism before diagnosis (mo).
Table 2. Comparisons of non-motor and motor deficits between 41 drug-induced par-
kinsonism patients with normal and reduced putamen FP-CIT uptake 
Group I (n = 28) Group II (n = 13) p value
Non-motor deficits
RBD 3 (10.7) 4 (30.8) 0.181
Hyposmia 3 (10.7) 6 (46.2) 0.018*
Urinary symptom 4 (14.3) 5 (38.5) 0.113
Urgency 3 (10.7) 3 (23.1) 0.361
Urge incontinence 3 (10.7) 5 (38.5) 0.084
Postural dizziness 11 (39.3) 8 (61.5) 0.313
Erectile dysfunction 2/5 (40.0) 4/5 (80.0) 0.524
Constipation 15 (53.6) 7 (53.8) 0.987
MMSE 23.39 ± 1.92 24.46 ± 5.35 0.555
Dementia (MMSE ≤ 24) 9 (39.1) 4 (30.8) 0.727
Motor deficits 
Falls 7 (25.0) 5 (38.5) 0.469
Aspiration 2 (7.1) 2 (15.4) 0.579
Dysarthria 10 (35.7) 5 (38.5) > 0.999
BLM dyskinesia 5 (17.9) 1 (7.7) 0.645
Initial symptoms 0.271
Tremors 13 (46.4) 3 (23.1)
Gait disturbance 6 (21.4) 7 (53.8)
Bradykinesia 5 (17.9) 2 (15.4)
Dysarthria 2 (7.1) 1 (7.7)
Dyskinesia 2 (7.1) 0 (0)
Asymmetric onset 9 (32.1) 5 (38.5) 0.734
Group I: normal putamen FP-CIT uptake, Group II: reduced putamen FP-CIT uptake. Mean 
± standard deviation, numbers in parentheses = %. *p-value < 0.05. RBD: rapid eye move-
ment sleep behavior disorder, MMSE: Mini-Mental Status Examination, BLM: bucco-linguo-
masticatory. 
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tients with reduced putamen DAT uptake had been 
exposed to CCBs. They showed deterioration or less 
improvement in UPDRS total motor scores and sub-
scores for bradykinesia and tremors after drug with-
drawal. However, only hyposmia was associated in-
dependently with abnormal scans at baseline.
A DAT SPECT study reported that DIP patients 
with abnormal scans were significantly older than 
those with normal scans.9 However, the present study 
and other studies have shown no significant differ-
ence in age of onset.1-4,10,15
An Italian group reported no female predomi-
nance in DIP patients with normal and reduced stri-
atal DAT uptake.4,9 However, two other studies from 
the same group and the present study found similar 
female predominance in DIP patients with normal 
and abnormal scans.2,3 These findings suggest the 
high vulnerability of females to DIP, even in females 
with reduced nigrostriatal dopaminergic innerva-
tion.16
An FP-CIT PET study reported lower symmetric 
frequency of parkinsonism in the abnormal scan 
than the normal scan.10 However, the present study 
showed no significant difference in asymmetric par-
kinsonism as measured by frequency, UPDRS score 
and asymmetry index. The previous study also showed 
that the interval from drug intake to the onset of par-
kinsonian symptoms was longer in patients with an 
abnormal scan than a normal scan. However, the pres-
ent study showed no significant difference between 
the two groups.
The drug exposure period before the onset of par-
kinsonism was longer in patients treated with CCBs 
than those treated with dopamine blockers.17 Tremor 
was the main symptom induced by CCBs, whereas ri-
gidity was the most common feature induced by other 
offending drugs.17 In the present study, eight patients 
with normal scans had taken CCBs, while none with 
abnormal scans had taken CCBs (p = 0.040). Al-
though the difference was not significant using re-
gression analyses, large studies are needed to deter-
mine whether CCBs can rarely uncover subclinical 
nigrostriatal dopaminergic degeneration.
A DAT SPECT study of DIP reported that patients 
with abnormal scans had abnormal odor threshold, 
discrimination and identification, while patients 
with normal scans had abnormal odor threshold.18 
In the present study, 46% of patients with abnormal 
scans reported hyposmia compared to 11% of those 
with normal scans. Although a history of hyposmia 
was an independent factor, its suboptimal sensitivity 
for the detection of abnormal scans in DIP limits its 
use in clinical practice.
In the present study, 39% of patients with abnor-
mal scans had urge incontinence. Their mean dura-
tion of parkinsonism was only one year. Postmortem 
pathological studies are needed to define how many 
of these patients have multiple system atrophy.
A DAT SPECT study of DIP reported that BLM 
dyskinesia is more frequent in patients with normal 
scans than in those with abnormal scans. Most pa-
tients included in that study had schizophrenia and 
were being treated with neuroleptics.2 The present 
study of patients with different illnesses treated using 
a variety of drugs did not show differences in the fre-
quency of BLM dyskinesia.15
No previous dopaminergic brain imaging studies 
compared differences in the initial symptoms of DIP 
patients with normal and abnormal scans. Only one 
PET study compared the frequency of tremors at rest 
and orolingual dyskinesia.10 However, they did not 
compare other initial symptoms. In the present study, 
the most common initial symptoms were tremors in 
patients with normal scans and gait disturbances in 
patients with abnormal scans. However, there were 
no significant group differences in the frequencies of 
initial symptoms, including asymmetric onset.
Two SPECT studies and one PET study reported 
that DIP patients with abnormal scans had more se-
vere and asymmetric parkinsonism.2,4,10 However, in 
the present study, patients with abnormal scans had 
no significant differences in UPDRS motor scores 
nor the frequencies and severities of asymmetric 
parkinsonism.1,9 The present study also showed no 
significant group differences in UPDRS subscores 
for axial motor deficits and indexes for dispropor-
tionate upper-to-lower involvement of the extremi-
ties.
Complete recovery after drug withdrawal has been 
considered an indicator of normal nigrostriatal do-
paminergic function in patients with DIP.15,19 In the 
present study, none of the UPDRS changes indepen-
dently indicated an abnormal scan. In addition, pa-
tients with normal and abnormal scans showed a 
similar degree of residual parkinsonian motor defi-
cits.
In conclusion, among 32 baseline clinical parame-
ters and changes in UPDRS scores after drug with-
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drawal, only hyposmia was independently associated 
with nigrostriatal dopaminergic degeneration in pa-
tients with DIP. However, hyposmia does not appear 
to be a practical indicator of abnormal scans. Dopa-
minergic functional imaging studies are needed to 
detect nigrostriatal degeneration in patients clinically 
diagnosed with DIP.
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